Moderna, Inc. Common Stock MRNA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-03T13:41:30.659Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-06
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T13:27:58.920780045Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-01T23:56:28.143793+00:00
Earnings observationsAlpha Vantage · collected 2026-11-01T23:56:15.824692+00:00
Moderna, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 246.84 | 136.3% | 12.4% | 199.50 | 143.8% | 11.8% |
| 25Δ | 242.04 | 137.7% | 10.7% | 204.20 | 140.7% | 10.1% |
| 30Δ | 237.71 | 138.9% | 9.2% | 207.75 | 146.1% | 9.2% |
| 35Δ | 233.40 | 137.1% | 7.8% | 212.11 | 136.1% | 7.6% |
| 40Δ | 229.85 | 140.3% | 6.8% | 215.54 | 138.5% | 6.8% |
| 45Δ | 226.16 | 140.7% | 5.8% | 219.02 | 137.0% | 6.0% |
| 50Δ | 222.52 | 138.9% | 4.8% | 222.46 | 136.5% | 5.2% |
| 55Δ | 219.01 | 139.7% | 4.0% | 225.95 | 136.2% | 4.5% |
| 60Δ | 215.50 | 140.4% | 3.2% | 229.84 | 140.2% | 4.0% |
| 65Δ | 211.73 | 143.7% | 2.6% | 234.01 | 143.0% | 3.5% |
| 70Δ | 207.49 | 149.8% | 2.1% | 238.32 | 143.1% | 2.9% |
| 75Δ | 203.67 | 146.0% | 1.5% | 242.70 | 141.4% | 2.4% |
| 80Δ | 199.39 | 144.5% | 0.9% | 247.55 | 139.4% | 2.0% |
20Δ
- Pseudo strike
- 246.84
- IV
- 136.3%
- B/E move
- 12.4%
- Pseudo strike
- 199.50
- IV
- 143.8%
- B/E move
- 11.8%
25Δ
- Pseudo strike
- 242.04
- IV
- 137.7%
- B/E move
- 10.7%
- Pseudo strike
- 204.20
- IV
- 140.7%
- B/E move
- 10.1%
30Δ
- Pseudo strike
- 237.71
- IV
- 138.9%
- B/E move
- 9.2%
- Pseudo strike
- 207.75
- IV
- 146.1%
- B/E move
- 9.2%
35Δ
- Pseudo strike
- 233.40
- IV
- 137.1%
- B/E move
- 7.8%
- Pseudo strike
- 212.11
- IV
- 136.1%
- B/E move
- 7.6%
40Δ
- Pseudo strike
- 229.85
- IV
- 140.3%
- B/E move
- 6.8%
- Pseudo strike
- 215.54
- IV
- 138.5%
- B/E move
- 6.8%
45Δ
- Pseudo strike
- 226.16
- IV
- 140.7%
- B/E move
- 5.8%
- Pseudo strike
- 219.02
- IV
- 137.0%
- B/E move
- 6.0%
50Δ
- Pseudo strike
- 222.52
- IV
- 138.9%
- B/E move
- 4.8%
- Pseudo strike
- 222.46
- IV
- 136.5%
- B/E move
- 5.2%
55Δ
- Pseudo strike
- 219.01
- IV
- 139.7%
- B/E move
- 4.0%
- Pseudo strike
- 225.95
- IV
- 136.2%
- B/E move
- 4.5%
60Δ
- Pseudo strike
- 215.50
- IV
- 140.4%
- B/E move
- 3.2%
- Pseudo strike
- 229.84
- IV
- 140.2%
- B/E move
- 4.0%
65Δ
- Pseudo strike
- 211.73
- IV
- 143.7%
- B/E move
- 2.6%
- Pseudo strike
- 234.01
- IV
- 143.0%
- B/E move
- 3.5%
70Δ
- Pseudo strike
- 207.49
- IV
- 149.8%
- B/E move
- 2.1%
- Pseudo strike
- 238.32
- IV
- 143.1%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- 203.67
- IV
- 146.0%
- B/E move
- 1.5%
- Pseudo strike
- 242.70
- IV
- 141.4%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- 199.39
- IV
- 144.5%
- B/E move
- 0.9%
- Pseudo strike
- 247.55
- IV
- 139.4%
- B/E move
- 2.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 82.47% | |
| 69.79% | |
| 70.82% | |
| 74.86% | |
| 71.70% | |
| 68.76% | |
| 67.51% | |
| 65.08% | |
| 68.47% | |
| 68.44% | |
| 194.02% | |
| 146.95% | |
| 110.44% | |
| 105.46% | |
| 109.65% | |
| 89.52% | |
| 81.09% | |
| 72.50% | |
| 81.80% | |
| 87.44% | |
| 80.67% | |
| 78.62% | |
| 70.14% | |
| 74.38% | |
| 70.99% | |
| 67.38% | |
| 69.55% | |
| 77.79% | |
| 75.80% | |
| 76.58% | |
| 78.97% | |
| 63.20% | |
| 80.49% | |
| 78.30% | |
| 78.47% | |
| 84.51% | |
| 79.24% | |
| 81.66% | |
| 83.98% | |
| 82.80% | |
| 81.07% | |
| 82.51% | |
| 89.94% | |
| 90.43% | |
| 88.61% | |
| 93.59% | |
| 102.12% | |
| 100.13% | |
| 103.19% | |
| 108.57% | |
| 112.31% | |
| 117.62% | |
| 131.66% | |
| 131.22% | |
| 133.89% | |
| 116.16% | |
| 102.15% | |
| 93.13% | |
| 99.72% | |
| 96.03% | |
| 93.31% | |
| 92.17% |
Biotechnology
MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human…
More →NAMS
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its…
More →NAUT
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is…
More →NBTX
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
More →NGNE
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical…
More →NKTR
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad,…
More →